MA49841A - Carboxamides utilisées en tant qu'inhibiteurs de protéase spécifique de l'ubiquitine - Google Patents

Carboxamides utilisées en tant qu'inhibiteurs de protéase spécifique de l'ubiquitine

Info

Publication number
MA49841A
MA49841A MA049841A MA49841A MA49841A MA 49841 A MA49841 A MA 49841A MA 049841 A MA049841 A MA 049841A MA 49841 A MA49841 A MA 49841A MA 49841 A MA49841 A MA 49841A
Authority
MA
Morocco
Prior art keywords
ubiquitine
protease inhibitors
specific protease
carboxamides used
carboxamides
Prior art date
Application number
MA049841A
Other languages
English (en)
French (fr)
Inventor
Justin Caravella
Davidj Guerin
Stephanos Ioannidis
Hongbin Li
Pui Yee Ng
Tatiana Shelekhin
Zhongguo Wang
Mary-Margaret Zablocki
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of MA49841A publication Critical patent/MA49841A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA049841A 2017-08-11 2018-08-09 Carboxamides utilisées en tant qu'inhibiteurs de protéase spécifique de l'ubiquitine MA49841A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762544083P 2017-08-11 2017-08-11

Publications (1)

Publication Number Publication Date
MA49841A true MA49841A (fr) 2020-06-17

Family

ID=63405399

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049841A MA49841A (fr) 2017-08-11 2018-08-09 Carboxamides utilisées en tant qu'inhibiteurs de protéase spécifique de l'ubiquitine

Country Status (9)

Country Link
US (1) US11524966B1 (zh)
EP (1) EP3665169A1 (zh)
JP (1) JP2020530469A (zh)
AR (1) AR112468A1 (zh)
AU (1) AU2018316254B2 (zh)
CA (1) CA3072449A1 (zh)
MA (1) MA49841A (zh)
TW (1) TW201920157A (zh)
WO (1) WO2019032863A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3665169A1 (en) 2017-08-11 2020-06-17 Forma Therapeutics, Inc. Carboxamides as ubiquitin-specific protease inhibitors
BR112021002408A2 (pt) * 2018-08-09 2021-05-04 Valo Early Discovery, Inc. carboxamidas como inibidores da protease específica de ubiquitina
CN116410207A (zh) * 2019-05-09 2023-07-11 杭州普济远成生物医药科技有限公司 一类泛素化特异性蛋白酶抑制剂及其制备方法与应用
CN111943879A (zh) * 2020-08-03 2020-11-17 南通大学 一种（3s，4r）3-氨基-4（甲氧基甲基）吡咯烷-1-甲酸叔丁酯及其合成方法
CN116969976A (zh) * 2022-04-28 2023-10-31 杭州普济远成生物医药科技有限公司 去泛素化酶抑制剂及其应用
CN115974747A (zh) * 2022-09-30 2023-04-18 上海北卡医药技术有限公司 一种3-（3-氯丙基）-4-氧代吡咯烷-1-羧酸乙酯的制备方法及用途
CN117916246A (zh) * 2022-12-01 2024-04-19 杭州普济远成生物医药科技有限公司 泛素化特异性蛋白酶抑制剂盐型、晶型及其制备方法与应用
WO2024114793A1 (zh) * 2022-12-01 2024-06-06 杭州普济远成生物医药科技有限公司 泛素化特异性蛋白酶抑制剂盐型、晶型及其制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078934A2 (en) 1999-06-22 2000-12-28 School Of Pharmacy, University Of London Use of the ubiquitin specific protease usp25 in the diagnosis and treatment of alzheimer's disease
WO2005037845A1 (en) 2003-10-17 2005-04-28 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole[5,5-b] pyridine compositions and their use as ubiquitin ligase inhibitors
SE0403171D0 (sv) 2004-12-23 2004-12-23 Astrazeneca Ab New compounds
UY32443A (es) 2009-02-13 2010-09-30 Sanofi Aventis Nuevos tetrahidronaftalenos, procesos para su preparación y uso de los mismos como medicamento.
EP2400845B1 (en) 2009-02-27 2017-02-22 Siga Technologies, Inc. Thienopyridine derivatives for the treatment and prevention of dengue virus infections
WO2012040527A2 (en) 2010-09-24 2012-03-29 The Regents Of The University Of Michigan Deubiquitinase inhibitors and methods for use of the same
CA2896731A1 (en) 2012-12-28 2014-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
JP2016506929A (ja) 2013-01-23 2016-03-07 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ヒト銅輸送タンパク質ａｔｏｘ１およびｃｃｓを阻害するための方法および組成物
US10889592B2 (en) 2016-02-12 2021-01-12 Valo Early Discovery, Inc. Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors
CN109071560B (zh) 2016-02-12 2022-01-14 瓦洛健康公司 用作泛素特异性蛋白酶抑制剂的噻吩并吡啶甲酰胺
EP3665169A1 (en) 2017-08-11 2020-06-17 Forma Therapeutics, Inc. Carboxamides as ubiquitin-specific protease inhibitors

Also Published As

Publication number Publication date
CA3072449A1 (en) 2019-02-14
AU2018316254A1 (en) 2020-02-20
AR112468A1 (es) 2019-10-30
JP2020530469A (ja) 2020-10-22
WO2019032863A1 (en) 2019-02-14
EP3665169A1 (en) 2020-06-17
US11524966B1 (en) 2022-12-13
TW201920157A (zh) 2019-06-01
AU2018316254B2 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA49841A (fr) Carboxamides utilisées en tant qu'inhibiteurs de protéase spécifique de l'ubiquitine
MA49566A (fr) Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
MA53275A (fr) Carboxamides en tant qu'inhibiteurs de protéase spécifiques de l'ubiquitine
MA49903A (fr) Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
MA40943A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA40940A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA51878A (fr) Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
MA44725A (fr) Formulations d'un inhibiteur de lsd1
MA41291A (fr) Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
MA42032A (fr) Acides 3-aryl-4-amido-bicyclo [4,5,0]hydroxamiques en tant qu'inhibiteurs de hdac
MA45192A (fr) Traitement d'association
MA40587A (fr) Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
DK3889145T3 (da) 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme
MA53150A (fr) Composés de benzimidazole en tant qu'inhibiteurs de c-kit
MA41551A (fr) Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
DK3212662T3 (da) Serinproteaser
MA52123A (fr) Dérivé de 6-pyrimidine-isoindole utilisé en tant qu'inhibiteur de erk1/2
MA46180A (fr) Analogues de l'amyline
DK3212781T3 (da) Serinproteaser
CL2017002973S1 (es) Botella (divisional solicitud 201700051)
MA46746A (fr) Amides d'azole et amines en tant qu'inhibiteurs d'intégrine alpha v
DK3558278T3 (da) Flydende cannabinoidsammensætning